1. Could Amgen’s latest bad news boost their interest in acquisitions? — Senators urge FTC to scrutinize pharma mega-mergers — Merck’s Keytruda combo wins simultaneous approvals in US, Canada, and Australia — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, May 17, 2019 at 1:12 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    12,011
    Likes Received:
    3
    via Already beavering away at building a US commercial operation, MorphoSys {$MOR} is now bearing down on Novartis and Gilead with a potential CAR-T killer soon to be put into the hands of US regulators.

    article source